Monia Casamenti, a 44-year-old mother of two from Forlì, is campaigning for access to the innovative pancreatic cancer drug daraxonrasib, according to ForlìToday. Currently hospitalized at the Irst of Meldola, she has launched a crowdfunding campaign on GoFundMe to pursue the treatment, which is not yet covered by the Italian national health system.
How was the diagnosis received?
Monia Casamenti discovered her diagnosis in early September through her online health portal, rather than through a direct conversation with medical staff. “Nessuno si è premurato di chiamarmi al telefono, di comunicarmelo guardandomi negli occhi,” she told ForlìToday. After experiencing abdominal pain in August, she was initially advised to take pain relief.
Subsequent symptoms, including jaundice, led her to seek care in Cesena, where she underwent biopsies before receiving the results via the digital health record system, ForlìToday reported. At the fundraising page “mamma con tumore al pancreas cerca aiuto,” supporters can contribute to assist her in accessing the medication.
What is the status of the treatment?
The drug daraxonrasib, developed by Revolution Medicines, is an oral medication that inhibits RAS proteins to slow tumor growth. While it received European authorization on November 16, it is not yet reimbursed by the Italian National Health Service, as reported by Sanità Informazione. A phase 3 study, RASolute 302, involving 500 patients, showed that the drug increased median survival to 13.2 months compared to 6.6 months with standard chemotherapy, according to SKY.
Data presented at the American Society of Clinical Oncology (ASCO) 2026 congress and published in the New England Journal of Medicine indicate that at six months, survival was 77.7% with daraxonrasib compared to 54.9% with chemotherapy. While the drug can reduce tumors by a modest amount, “il cancro spesso sviluppa resistenza e ricomincia a crescere,” as noted in reports from Il Sole 24 Ore.

FDA Approves Drug for Metastatic Pancreatic Cancer in August 2026
In the United States, the Food and Drug Administration approved the drug on August 26, 2026, for adult patients with metastatic pancreatic adenocarcinoma who have previously undergone systemic therapy or are ineligible for multi-drug systemic treatments. Revolution Medicines previously activated an Expanded Access Program in the U.S. that provided free drug distribution through a network of oncology centers before commercial authorization.
According to data shared by the company and cited by the Lombardy Region, this program had already involved over 2,000 patients by August 2026. Eleven patient advocacy organizations are now urging an urgent meeting with the manufacturer, AIFA, and the Ministry of Health to define a shared path for Italian patients.
How are authorities responding to patient requests?
Eleven patient advocacy groups are calling for free access to the medication for those who meet clinical requirements, an appeal supported by the Lombardy Region, according to Sanità Informazione. Regional Welfare Councilor Guido Bertolaso confirmed that Lombardy is ready to act as a bridge between the Italian Medicines Agency (AIFA), the Ministry of Health, and the manufacturer to facilitate a national access program, reported Corriere della Sera.
The region has already provided emergency funding for another patient, Jessica, to access the drug. “Vogliamo verificare se e come questo modello possa essere adattato alla realtà italiana, nel pieno rispetto delle competenze delle autorità regolatorie e delle valutazioni dei medici,” said Bertolaso.

| Treatment Group | Estimated Survival at 6 Months |
|---|---|
| Daraxonrasib | 77.7% |
| Chemotherapy | 54.9% |
What is next for patients seeking the drug?
While AIFA announced on November 18 that it has begun a progressive evaluation of data to accelerate national procedures, a formal national program for free distribution has not yet been activated. “L’obiettivo è uno solo: non lasciare che pazienti come Jessica perdano, per ragioni economiche o amministrative, la possibilità di accedere a trattamenti che possono contribuire a prolungare la sopravvivenza,” said Bertolaso, as cited by Quotidiano Sanità.
Casamenti, who is currently undergoing chemotherapy, remains hopeful for a chance to access the therapy. “Io vorrei tentare con questa pillola, vorrei almeno avere una chance per continuare a vivere,” she told ForlìToday. The availability shown by the Lombardy Region represents an initial institutional support, but the program has not yet been officially activated.